AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company that develops and commercializes medications in medically supervised settings. Two of the company's medicines for moderate-to-severe acute pain are DSUVIA and Zalviso. ARX-02 and ARX-03 are two forthcoming products from the firm.

Why should Investors make an Exit?

• Fall-in topline and continuous losses: ACRX witnessed a significant decline in total revenue to USD 2.82 million in FY21 (ended December 31, 2021) from USD 5.42 million in FY20. It is a loss-making entity and incurred a loss of USD 35.10 million in FY21 and USD 40.38 million in FY20 due to higher operating costs, resulting in negative profit margins.
• Macro Headwinds: Unless organic cash from normal business operations is robust, recent market discussions about raising interest rates sooner to combat inflation will pressure the corporation to increase short-term borrowing for working capital. This is a temporary stumbling hurdle that makes it less appealing to investors.
• Bearish Technical Indicator: On the daily chart, ACRX prices are sustaining below the downward sloping trend line and facing the resistance of the same. Furthermore, the momentum oscillator RSI (14-period) is trading at ~34.21. On the weekly chart, the prices are trading below the trend-following indicators 21-period and 50-period SMA, which may act as a resistance level for the stock.

Valuation Methodology: Price/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

Stock Recommendation:

ACRX's share price has remained on a bearish trend, fallen 82.41% in the past twelve months and is currently leaning close to the lower end of its 52-week range of USD 0.27 to USD 1.72. We have valued the stock using the Price/ Sales multiple based on relative valuation methodology and arrived at a target price of USD 0.23.

Based on the continuous losses, decline in topline, macro headwinds, current valuation, and bearish technical indicators, we recommend a "Sell" rating on the stock at the current price of USD 0.2832, up 1.36%, as of March 30, 2022.

Three-Year Technical Price Chart (as of March 30, 2022). Source: REFINITIV, Analysis by Kalkine Group

*All forecasted figures and Industry Information have been taken from REFINITIV.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.